Pregnancy outcome in patients with stage 1a endometrial adenocarcinoma, who conservatively treated with megestrol acetate

Archives of Gynecology and Obstetrics

Volumn 285, Issue 3, 2012, Pages 791-795

  Shirali, Elham ^a   Yarandi, Fariba ^b   Eftekhar, Zahra ^b   Shojaei, Hadi ^b   Khazaeipour, Zahra ^b,c   Hoellen, Friederike ^c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hormonal therapy; Pregnancy; Progesterone receptor; Well differentiated endometrial carcinoma

Indexed keywords

ESTROGEN RECEPTOR; MEGESTROL ACETATE; PROGESTERONE RECEPTOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CURETTAGE; DOWN SYNDROME; ENDOMETRIUM CARCINOMA; FEMALE; FERTILIZATION IN VITRO; FOLLOW UP; HORMONAL THERAPY; HUMAN; HYDATIDIFORM MOLE; HYSTEROSCOPY; PATIENT REFERRAL; PREGNANCY; PREGNANCY OUTCOME; QUASI EXPERIMENTAL STUDY; SPONTANEOUS ABORTION; TREATMENT RESPONSE; ADENOCARCINOMA; ENDOMETRIUM TUMOR; HYSTERECTOMY; PREGNANCY COMPLICATION; REPRODUCTIVE PROCEDURE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ENDOMETRIAL NEOPLASMS; FEMALE; FERTILITY PRESERVATION; HUMANS; HYSTERECTOMY; MEGESTROL ACETATE; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PREGNANCY OUTCOME; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863211658     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-011-2021-8     Document Type: Article

References (17)

1. Bakkum-Gamez JN, Gonzalez-Bosquet J, Laack NN, Mariani A, Dowdy SC (2008) Current issues in the management of endometrial cancer. Mayo Clin Proc 83(1):97-112 (review).
2. Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C (2004) Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 95:133-138.
3. Key TJ, Pike MC (1988) The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial. Cancer risk Br J Cancer 57(2):205-212.
4. Setiawan VW, Doherty JA, Shu XO, Akbari MR, Chen C, De Vivo I, Demichele A, Garcia-Closas M, Goodman MT, Haiman CA, Hankinson SE, Henderson BE, Horn-Ross PL, Lacey JV Jr, Le Marchand L, Levine DA, Liang X, Lissowska J, Lurie G, McGrath M, Narod SA, Rebbeck TR, Ursin G, Weiss NS, Xiang YB, Yang HP, Zheng W, Olson SH (2009) Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer Epidemiol Biomarkers Prev 18(1):242-247.
5. Frumovitz M, Gershenson DM (2006) Fertility-sparing therapy for young women with endometrial cancer. Expert Rev Anticancer Ther 6:27-32.
6. Boing C, Kimmig R (2006) Fertility-preserving treatment in young women with endometrial cancer. Gynakol Geburtshilfliche Rundsch 46:25-33.
7. Podczaski E, Mortel R (2001) Hormonal treatment of endometrial cancer: past, present and future. Best Pract Res Clin Obstet Gynaecol 15:469-489.
8. Yang YC, Wu CC, Chen CP, Chang CL, Wang KL (2005) Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer. Gynecol Oncol 99:287-293.
9. Eftekhar Z, Izadi-Mood N, Yarandi F, Shojaei H, Rezaei Z, Mohagheghi S (2009) Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer 19(2):249-252.
10. Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ (1997) Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 79:320-327.
11. Yahata T, Fujita K, Aoki Y, Tanaka K (2006) Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod 21(4):1070-1075. Epub 2005 Dec. PubMed PMID: 16361282.
12. Zivanovic O, Carter J, Kauff ND, Barakat RR (2009) A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. Gynecol Oncol 115(3):504-509. (Epub 2009 Sep 15).
13. Lai CH, Huang HJ (2006) The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. Curr Opin Obstet Gynecol 18(1):29-34.
14. Markman M (2005) Hormonal therapy of endometrial cancer. Eur J Cancer 41(5):673-675.
15. Ota T, Yoshida M, Kimura M, Kinoshita K (2005) Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer 15:657-662.
16. Niwa K, Tagami K, Lian Z, Onogi K, Mori H, Tamaya T (2005) Outcome of fertility-preserving treatment in young women with endometrial carcinomas. Bjog 112:317-320.
17. Mousavi AS, Behtash N, Karimi Zarchi M, Modarres Gilani M, Ghaemmaghami F (2007) Fertility preservation in young women with endometrial carcinoma; report of three cases. Tehran Univ Med J 65(2):82-87